| Gene symbol | NPM1 | Synonyms | B23, NPM | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q35.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | nucleophosmin 1 | ||||
| GTO ID | GTC3888 |
| Trial ID | NCT06424340 |
| Disease | Acute Myeloid Leukemia |
| Altered gene | NPM1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | MB-dNPM1-TCR.1 |
| HLA | HLA-A*02:01 |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | A Phase I/II Trial of MB-dNPM1-TCR.1 in HLA-A*02:01-positive Patients With Relapsed or Refractory NPM1-mutated AML to Determine Safety and Obtain First Data on Efficacy |
| Year | 2024 |
| Country | Germany |
| Company sponsor | Miltenyi Biomedicine GmbH |
| Other ID(s) | M-2020-358 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||